Literature DB >> 21519925

Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.

Takashi Yoshino1, Hiroko Tabunoki, Shigeo Sugiyama, Keitaro Ishii, Seung U Kim, Jun-Ichi Satoh.   

Abstract

A synthetic analog of sphingosine named FTY720 (Fingolimod), phosphorylated by sphingosine kinase-2, interacts with sphingosine-1-phosphate (S1P) receptors expressed on various cells. FTY720 suppresses the disease activity of multiple sclerosis (MS) chiefly by inhibiting S1P-dependent egress of autoreactive T lymphocytes from secondary lymphoid organs, and possibly by exerting anti-inflammatory and neuroprotective effects directly on brain cells. However, at present, biological effects of FTY720 on human microglia are largely unknown. We studied FTY720-mediated apoptosis of a human microglia cell line HMO6. The exposure of HMO6 cells to non-phosphorylated FTY720 (FTY720-non-P) induced apoptosis in a dose-dependent manner with IC50 of 10.6 ± 2.0 μM, accompanied by the cleavage of caspase-7 and caspase-3 but not of caspase-9. The apoptosis was inhibited by Z-DQMD-FMK, a caspase-3 inhibitor, but not by Pertussis toxin, a Gi protein inhibitor, suramin, a S1P3/S1P5 inhibitor, or W123, a S1P1 competitive antagonist, although HMO6 expressed S1P1, S1P2, and S1P3. Furthermore, both phosphorylated FTY720 (FTY720-P) and SEW2871, S1P1 selective agonists, did not induce apoptosis of HMO6. Genome-wide gene expression profiling and molecular network analysis indicated activation of transcriptional regulation by sterol regulatory element-binding protein (SREBP) in FTY720-non-P-treated HMO6 cells. Western blot verified activation of SREBP2 in these cells, and apoptosis was enhanced by pretreatment with simvastatin, an activator of SREBP2, and by overexpression of the N-terminal fragment of SREBP2. These observations suggest that FTY720-non-P-induced apoptosis of HMO6 human microglia is independent of S1P receptor binding, and positively regulated by the SREBP2-dependent proapoptotic signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519925     DOI: 10.1007/s10571-011-9698-x

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  40 in total

1.  FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.

Authors:  Terence K Lee; Kwan Man; Joanna W Ho; Chris K Sun; Kevin T Ng; Xiang Hong Wang; Yong Chuan Wong; Irene O Ng; Ray Xu; Sheung Tat Fan
Journal:  Carcinogenesis       Date:  2004-08-05       Impact factor: 4.944

2.  Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.

Authors:  Ruben Van Doorn; Jack Van Horssen; Dennis Verzijl; Maarten Witte; Eric Ronken; Bert Van Het Hof; Kim Lakeman; Christine D Dijkstra; Paul Van Der Valk; Arie Reijerkerk; Astrid E Alewijnse; Stephan L M Peters; Helga E De Vries
Journal:  Glia       Date:  2010-09       Impact factor: 7.452

Review 3.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

4.  The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity.

Authors:  Padmavathi Bandhuvula; Yuen Yee Tam; Babak Oskouian; Julie D Saba
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

5.  Fingolimod provides long-term protection in rodent models of cerebral ischemia.

Authors:  Ying Wei; Muge Yemisci; Hyung-Hwan Kim; Lai Ming Yung; Hwa Kyoung Shin; Seo-Kyoung Hwang; Shuzhen Guo; Tao Qin; Nafiseh Alsharif; Volker Brinkmann; James K Liao; Eng H Lo; Christian Waeber
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

6.  FTY720 modulates human oligodendrocyte progenitor process extension and survival.

Authors:  Veronique E Miron; Cha Gyun Jung; Hye Jung Kim; Timothy E Kennedy; Betty Soliven; Jack P Antel
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

7.  CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Authors:  Yi Jin; Markus Zollinger; Hubert Borell; Alfred Zimmerlin; Christopher J Patten
Journal:  Drug Metab Dispos       Date:  2010-11-02       Impact factor: 3.922

8.  Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.

Authors:  J D Wang; S Takahara; N Nonomura; N Ichimaru; K Toki; H Azuma; K Matsumiya; A Okuyama; S Suzuki
Journal:  Prostate       Date:  1999-06-15       Impact factor: 4.104

9.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

Authors:  Z Xia; M M Tan; W W Wong; J Dimitroulakos; M D Minden; L Z Penn
Journal:  Leukemia       Date:  2001-09       Impact factor: 11.528

10.  Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells.

Authors:  Yasuo Nagaoka; Kota Otsuki; Tetsuro Fujita; Shinichi Uesato
Journal:  Biol Pharm Bull       Date:  2008-06       Impact factor: 2.233

View more
  11 in total

Review 1.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

2.  UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort.

Authors:  Jose Manuel Vidal-Taboada; Alan Lopez-Lopez; Maria Salvado; Laura Lorenzo; Cecilia Garcia; Nicole Mahy; Manuel J Rodríguez; Josep Gamez
Journal:  J Neurol       Date:  2015-07-11       Impact factor: 4.849

Review 3.  Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.

Authors:  Aran Groves; Yasuyuki Kihara; Jerold Chun
Journal:  J Neurol Sci       Date:  2013-03-19       Impact factor: 3.181

4.  Synthesis and Biological Evaluation of Fingolimod Derivatives as Antibacterial Agents.

Authors:  Matej Zore; Shella Gilbert-Girard; Inés Reigada; Jayendra Z Patel; Kirsi Savijoki; Adyary Fallarero; Jari Yli-Kauhaluoma
Journal:  ACS Omega       Date:  2021-07-09

5.  FTY720 attenuates excitotoxicity and neuroinflammation.

Authors:  Raffaela Cipriani; Juan Carlos Chara; Alfredo Rodríguez-Antigüedad; Carlos Matute
Journal:  J Neuroinflammation       Date:  2015-05-08       Impact factor: 8.322

6.  Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast.

Authors:  Kanako Hagihara; Ayako Kita; Aya Mizukura; Mariko Yao; Yuki Kitai; Tatsuki Kunoh; Takashi Masuko; Sumio Matzno; Kenji Chiba; Reiko Sugiura
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

Review 7.  More than Just an Immunosuppressant: The Emerging Role of FTY720 as a Novel Inducer of ROS and Apoptosis.

Authors:  Teruaki Takasaki; Kanako Hagihara; Ryosuke Satoh; Reiko Sugiura
Journal:  Oxid Med Cell Longev       Date:  2018-03-28       Impact factor: 6.543

8.  FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.

Authors:  Limin Chen; Liu-Fei Luo; Junyan Lu; Lianchun Li; Yuan-Fang Liu; Jiang Wang; Hong Liu; Heng Song; Hualiang Jiang; Sai-Juan Chen; Cheng Luo; Keqin Kathy Li
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

Review 9.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26

Review 10.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.